Through the last two decades, a phenomenal evolution of bispecific antibodies has developed in front of our eyes, with this “zoo” of bispecificity being populated by many different species: there are small molecules made exclusively of the antigenbinding sites of two antibodies; molecules with an Immunoglobulin G (IgG) structure; and, large complex molecules composed of different antigen-binding moieties, often combined with dimerization modules.

This whitepaper looks at:

• Latest industry developments, discoveries and investment in bispecific antibodies
• Emerging bispecific technologies/modes of action
• Current challenges facing (pre-)clinical development
• Discovery strategies
• Bispecific target discovery, identification and validation strategies.

BISPECIFIC ANTIBODY ENGINEERING
AND THERAPEUTICS